Log In
BCIQ
Print this Print this
 

ARG301

  Manage Alerts
Collapse Summary General Information
Company arGentis Pharmaceuticals LLC
DescriptionOligopeptide derived from human CII sequence
Molecular Target T cell receptor (TCR)
Mechanism of ActionImmune modulation
Therapeutic ModalityPeptide
Latest Stage of DevelopmentPhase I
Standard IndicationRheumatoid arthritis (RA)
Indication DetailsTreat Rheumatoid arthritis (RA)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today